- AGIO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $68.2 million.
- AGIO is up 3.7% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in AGIO with the Ticky from Trade-Ideas. See the FREE profile for AGIO NOW at Trade-Ideas More details on AGIO: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Currently there are 2 analysts that rate Agios Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Agios Pharmaceuticals has been 680,300 shares per day over the past 30 days. Agios has a market cap of $2.9 billion and is part of the health care sector and drugs industry. Shares are up 254.4% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Agios Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins.